Clinical trials in Bistrița

Researchers in Bistrița are conducting a trial that examines a novel antibody‑drug conjugate for patients with triple-negative breast cancer and other HER2‑negative tumors, aiming to identify the optimal dose and compare its effectiveness against standard chemotherapy options.

• Evaluation of a novel antibody‑drug conjugate
• Comparison with standard chemotherapy regimens
• Focus on patients with inoperable or metastatic disease
• Assessment of safety and efficacy

The study is actively recruiting, offering participants access to cutting‑edge treatment while contributing to improved therapeutic strategies for aggressive breast cancer subtypes.

An ongoing investigation in Bistrița focuses on adults with hereditary hemochromatosis caused by HFE gene mutations, testing the iron‑chelator vamifeport and measuring its impact on MRI‑based liver iron concentration.

• Evaluation of iron reduction therapy
• Use of MRI to monitor liver iron levels
• Inclusion of adult participants with HFE‑related disease
• Safety profile assessment

Recruitment is open, and the trial seeks to improve disease management by providing a targeted approach to reduce hepatic iron overload.